Screener
Xenon Pharmaceuticals XENE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from exercise of stock options | 5,513 | 1,216 |
| Net cash provided by financing activities | 843,039 | 1,216 |
| Effect of exchange rate changes on cash and cash equivalents | 132 | 568 |
| Decrease in cash and cash equivalents | (79,636) | (7,331) |
| Cash and cash equivalents, beginning of period | 199,163 | 142,712 |
| Cash and cash equivalents, end of period | $119,527 | $135,381 |
| Supplemental disclosure of cash paid: | ||
| Operating lease | $879 | $845 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's net change in cash?
- Xenon Pharmaceuticals (XENE) reported net change in cash of -$426.34M in Q2 2026.
- How has Xenon Pharmaceuticals's net change in cash changed year-over-year?
- Xenon Pharmaceuticals's net change in cash decreased by 2377.0% year-over-year, from $18.72M to -$426.34M.
- What is the long-term trend for Xenon Pharmaceuticals's net change in cash?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's net change in cash has grown at a -25.4% compound annual growth rate (CAGR), from $135.73M to $56.45M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Xenon Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude